​

Emergent BioSolutions (EBS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Emergent BioSolutions Revenue Highlights

Latest Revenue (Y)

$742.90M

Latest Revenue (Q)

$231.10M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Emergent BioSolutions Revenue by Period

Emergent BioSolutions Revenue by Year

DateRevenueChange
2025-12-31$742.90M-28.81%
2024-12-31$1.04B-0.54%
2023-12-31$1.05B-6.10%
2022-12-31$1.12B-36.99%
2021-12-31$1.77B12.45%
2020-12-31$1.58B42.61%
2019-12-31$1.11B41.36%
2018-12-31$782.40M39.49%
2017-12-31$560.90M14.75%
2016-12-31$488.80M-0.11%
2015-12-31$489.33M20.98%
2014-12-31$404.47M29.33%
2013-12-31$312.75M10.95%
2012-12-31$281.89M3.11%
2011-12-31$273.38M-4.47%
2010-12-31$286.17M21.89%
2009-12-31$234.79M31.49%
2008-12-31$178.55M-2.38%
2007-12-31$182.91M19.76%
2006-12-31$152.73M16.87%
2005-12-31$130.69M56.52%
2004-12-31$83.49M49.71%
2003-12-31$55.77M-28.99%
2002-12-31$78.54M73.35%
2001-12-31$45.31M-

Emergent BioSolutions generated $742.90M in revenue during NA 2025, up -28.81% compared to the previous quarter, and up 47.10% compared to the same period a year ago.

Emergent BioSolutions Revenue by Quarter

DateRevenueChange
2025-09-30$231.10M64.02%
2025-06-30$140.90M-36.59%
2025-03-31$222.20M14.12%
2024-12-31$194.70M-33.73%
2024-09-30$293.80M15.35%
2024-06-30$254.70M-15.21%
2024-03-31$300.40M8.60%
2023-12-31$276.60M2.26%
2023-09-30$270.50M-19.95%
2023-06-30$337.90M105.66%
2023-03-31$164.30M-50.24%
2022-12-31$330.20M37.64%
2022-09-30$239.90M-
2022-06-30$239.90M-21.98%
2022-03-31$307.50M-57.48%
2021-12-31$723.20M119.82%
2021-09-30$329.00M-17.23%
2021-06-30$397.50M15.89%
2021-03-31$343.00M-41.17%
2020-12-31$583.00M51.35%
2020-09-30$385.20M-2.41%
2020-06-30$394.70M105.04%
2020-03-31$192.50M-46.57%
2019-12-31$360.30M15.55%
2019-09-30$311.80M28.21%
2019-06-30$243.20M27.60%
2019-03-31$190.60M-29.59%
2018-12-31$270.70M55.93%
2018-09-30$173.60M-21.16%
2018-06-30$220.20M86.90%
2018-03-31$117.81M-39.21%
2017-12-31$193.81M29.70%
2017-09-30$149.43M48.29%
2017-06-30$100.77M-13.77%
2017-03-31$116.86M-22.95%
2016-12-31$151.66M6.12%
2016-09-30$142.91M40.82%
2016-06-30$101.49M-8.57%
2016-03-31$111.00M-33.97%
2015-12-31$168.10M1.92%
2015-09-30$164.94M30.79%
2015-06-30$126.11M98.19%
2015-03-31$63.63M-57.00%
2014-12-31$147.97M7.26%
2014-09-30$137.95M25.04%
2014-06-30$110.33M104.75%
2014-03-31$53.88M-45.08%
2013-12-31$98.11M10.11%
2013-09-30$89.10M8.09%
2013-06-30$82.44M91.27%
2013-03-31$43.10M-54.44%
2012-12-31$94.61M42.07%
2012-09-30$66.59M-5.38%
2012-06-30$70.38M39.89%
2012-03-31$50.31M-53.39%
2011-12-31$107.95M83.70%
2011-09-30$58.76M-33.33%
2011-06-30$88.14M375.59%
2011-03-31$18.53M-82.05%
2010-12-31$103.25M39.55%
2010-09-30$73.99M19.07%
2010-06-30$62.14M32.77%
2010-03-31$46.80M-13.02%
2009-12-31$53.80M24.34%
2009-09-30$43.27M-40.88%
2009-06-30$73.19M13.44%
2009-03-31$64.52M80.47%
2008-12-31$35.75M-36.84%
2008-09-30$56.60M30.16%
2008-06-30$43.48M1.79%
2008-03-31$42.72M-52.34%
2007-12-31$89.64M-

Emergent BioSolutions generated $231.10M in revenue during Q3 2025, up 64.02% compared to the previous quarter, and up 90.73% compared to the same period a year ago.

Emergent BioSolutions Revenue Breakdown

Emergent BioSolutions Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
Contracts and Grants$37.70M$30.00M$26.30M$41.40M$71.30M
Product$705.20M$908.70M$944.50M$966.20M-
Commercial Product-$398.90M$497.30M--
Service-$103.50M$72.80M--
Contract Development And Manufacturing-$104.90M$113.30M--
Contract Development And Manufacturing, Leases----$108.00M

Emergent BioSolutions's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (94.93%), and Contracts and Grants (5.07%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Sep 20
Product$143.80M$222.00M$130.30M$209.10M$639.20M$269.50M$249.10M$249.80M$302.20M$143.40M$305.70M-------
Contracts and Grants$4.90M$9.10M$10.60M$13.10M$20.00M$10.00M$6.70M$6.50M$6.60M$6.50M$7.10M$17.40M$7.30M$9.60M----
All Other Revenue---$20.30M--------------
Commercial Product---$45.30M$303.60M$95.30M------------
Service----$89.60M$13.90M$59.60M$13.20M--$17.70M-------
Contract Development And Manufacturing-------$14.20M$29.10M$15.20M$17.90M-------
Contract Development And Manufacturing, Leases-----------$200.00K$400.00K$104.20M$114.60M---
Contracted Operating Leases---------------$129.70M$146.60M$177.70M

Emergent BioSolutions's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (96.70%), and Contracts and Grants (3.30%).

Emergent BioSolutions Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 25Dec 24Dec 23Dec 22Dec 21
UNITED STATES$531.10M$889.50M$897.80M--
CANADA$75.00M$148.60M---
Other Geographical Area$136.80M$82.80M---
Services Segment-$104.90M$78.50M--
Non-US----$894.90M

Emergent BioSolutions's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (71.49%), Other Geographical Area (18.41%), and CANADA (10.10%).

Quarterly Revenue by Country

CountryDec 24Sep 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Services Segment$7.40M$14.30M$20.00M$14.20M$29.10M$15.20M--------------
UNITED STATES------$602.80M$49.80M$124.40M$112.50M$502.60M$60.20M$66.30M$56.40M$235.50M$102.40M$224.20M$63.90M$230.70M$170.20M
Non-US-------$190.20M$118.30M$195.00M$220.60M$268.80M$114.90M$81.50M$105.40M$99.80M$74.30M$84.30M$80.10M$86.00M

Emergent BioSolutions's latest quarterly revenue breakdown by geography, as of Dec 24: Services Segment (100.00%).

Emergent BioSolutions Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
SNDLSNDL$909.01M$197.75M
EBSEmergent BioSolutions$742.90M$231.10M
ORGOOrganogenesis$564.17M$150.86M
ESPREsperion Therapeutics$403.13M$87.31M
RIGLRigel Pharmaceuticals$294.28M$69.46M
SIGASIGA$94.60M$2.62M
AQSTAquestive Therapeutics$44.55M$10.00M
PRTAProthena$9.68M$2.42M
CRVSCorvus Pharmaceuticals--
OLMAOlema Pharmaceuticals--
CMPSCOMPASS Pathways--

EBS Revenue FAQ

What is Emergent BioSolutions’s yearly revenue?

Emergent BioSolutions's yearly revenue for 2025 was $742.9M, representing a decrease of -28.81% compared to 2024. The company's yearly revenue for 2024 was $1.04B, representing a decrease of -0.54% compared to 2023. EBS's yearly revenue for 2023 was $1.05B, representing a decrease of -6.10% compared to 2022.

What is Emergent BioSolutions’s quarterly revenue?

Emergent BioSolutions's quarterly revenue for Q3 2025 was $231.1M, a 64.02% increase from the previous quarter (Q2 2025), and a -21.34% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $140.9M, a -36.59% decrease from the previous quarter (Q1 2025), and a -44.68% decrease year-over-year (Q2 2024). EBS's quarterly revenue for Q1 2025 was $222.2M, a 14.12% increase from the previous quarter (Q4 2024), and a -26.03% decrease year-over-year (Q1 2024).

What is Emergent BioSolutions’s revenue growth rate?

Emergent BioSolutions's revenue growth rate for the last 3 years (2023-2025) was -29.20%, and for the last 5 years (2021-2025) was -58.11%.

What are Emergent BioSolutions’s revenue streams?

Emergent BioSolutions's revenue streams in c 25 are Contracts and Grants, and Product. Contracts and Grants generated $37.7M in revenue, accounting 5.07% of the company's total revenue, up 25.67% year-over-year. Product generated $705.2M in revenue, accounting 94.93% of the company's total revenue, down -22.39% year-over-year.

What is Emergent BioSolutions’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Emergent BioSolutions was Product. This segment made a revenue of $705.2M, representing 94.93% of the company's total revenue.